Scancell Share Discussion Threads

[supernumerary] 11/1/2021 21:48

ee - yes, although at the moment there's no bar for that, so we can't say how high new competitors have to jump - for the others one can at least hazard a guess.

The other great unknown is the extent to which the vaccine stops carriers, and particularly asymptomatic carriers. Any advance in that area would be a huge step forward. I'm hoping it will become clearer over the next 3 months or so.

[emptyend] 11/1/2021 21:29

Supernumerary, .....to add to your spec list, I think the killer point will prove to be the durability of protection. 95% protection from a vaccine that remains effective for many mutations, such that it lasts (say) 5 years rather than 1, would be a major advance.

[supernumerary] 11/1/2021 20:50

torquay - thanks, interesting, copied wholesale to Open Orphan thread.

[ivyspivey] 11/1/2021 20:46

Inanaco.
Yep other vectors may be better than live attenuated from a safety point of view but if the Codagenix one is proved safe and they had FPI in phase 1 today then it fits both the criteria that EmptyvEnd highlighted in his Kate Bingham post.
1.Single dose.
2. Intra nasal which is much easier and quicker to give particularly in developing countries.
Also many people think Intra nasal Vax may provide a longer immune response by IgG.
All of these new Covid Vax will find their niche and there is a place for many types.

[torquayfan] 11/1/2021 20:34

Apologies if posted before . . . "As placebo-controlled testing falls out of favour, vaccine developers eye blood markers and challenge trials to assess next-generation candidates" - here it's said that "230 2nd Gen vaccines (are) in development and about 60 being tested in humans".

The first paras - "Global health researchers breathed a collective sigh of relief last month after nations across Europe, North America and elsewhere issued emergency approvals of the first COVID-19 vaccines. But as the shots are rolled out, clinicians are scrambling to work out how to evaluate dozens of other, earlier-stage vaccine candidates. These could be less expensive, have fewer side effects or be easier to administer than those now in use — and they would bolster the world’s supply of COVID-19 immunizations, ensuring more rapid distribution to all countries.

The trouble is that finding would-be participants for placebo-controlled clinical trials has become more of a challenge. In these trials, half the volunteers receive a dummy shot and half the real thing, but neither participants nor researchers know who received which one until after the trial. People are less likely to chance receiving a placebo when they could get one of the various vaccines now authorized, two of which prevent COVID-19 with about 95% efficacy. As it is, many people taking part in placebo-controlled trials have already asked to drop out to ensure that they get immunized."

[supernumerary] 11/1/2021 20:03

gooosed - "Panorama assesses the impact on young people’s mental health. The arrival of a vaccine offers hope..."

Reminds me of an old girlfriend of mine. Rang me up late one night, "I'm in such pain - help, help". Or words to that effect. She was hopelessly incoherent, and given her chequered history I thought anything might be happening, so rushed round to try and help.

When I got there, anxious queries - "Where is it, what's wrong? What sort of pain?" Came the reply "Oh Freddie, you don't understand - it's mental pain!!!"
She was of course right as rain next morning, but forever after known as 'Mental Pain' :)

So that's what I think of whenever the media tells me that young people are having mental health problems. Any other such reminiscences?

Incidentally, apropos nothing at all, is anything actually happening here? I like to visit because it's such a nice calm backwater - everybody talks a lot, but actual movement is delightfully imperceptible. Must be very reassuring?

I guess spec for 2/3 gen vaccines includes oral administration + no cold chain + 95%+ efficacy + cost below $10/dose? Good to know you lot aren't interested in vulgar profit...

[inanaco] 11/1/2021 19:16

Ivy interesting



this is exactly what i said .. the virus is an easy target which is why the results are so good from the vaccines

which is why i think Scancell can sterilise ..

take a look

Some scientists don't see a role for a live vaccine in the covid-19 fight. "This is a stupid easy virus to vaccinate against," says Michael Farzan, a specialist at the Scripps Research Institute. He says the virus exposes its most important vulnerability, the spike protein, in a way that makes it a ready target for antibodies, which other vaccines can generate. "You only need live attenuated viruses when you don't have a safer one. In this case it brings a risk that is unnecessary. There's no need to have a live virus multiplying inside you."

[emptyend] 11/1/2021 18:55

At one point Bingham (and others) were asked about the improvements that could be available with a 2nd gen vaccine and the response included:1. Single dose2. Delivery methods that do not require needles and vialsShe also noted their investment in the challenge trials, and said they will be used for testing 2nd gen vaccines at pace.Also of note, the manufacturing facility in Scotland can supply the whole UK for a year with any variety of vaccine (except whole virus vaccine), but is yet to come on stream.It was also clear that they concentrated on backing only the vaccines which had early delivery potential....hence not really backing Moderna because they were only manufacturing in the USA and all their early production was committed to the USA. First Europe deliveries 3-4 months later. All the other vaccines they've backed can be distributed at fridge temperatures.

[inanaco] 11/1/2021 18:47

Nice rise today .... amazing how a car crash investment keeps going up

[inanaco] 11/1/2021 18:46

bermuda

we are talking delivery method to carry the Epitopes etc not delivery by amazon

in other words a inhaled Mrna i would suggest is extremely difficult, on the news yesterday even shaking the vial or removing the air by flicking the syringe was a no no as it breaks the lipid fat surrounding the MRNA

Gazza

still waiting your Risk/reward post on SCib1

ATB

[ivyspivey] 11/1/2021 18:45

Evening Bermuda,
Yes delivery method will likely be a key part of 2nd generation Vax.
In fact Codagenix who are saying their 1 dose intra nasal Vax based on an attenuated live virus Vax have their First phase 1 patient dosed today.
They describe their Vax as 2nd generational

[gooosed] 11/1/2021 18:20

Berm - while talking she mentioned glass vials & the shortage. Will be interesting to see when & what is in Scancells next update.

May be of interest tonight there's Panorama BBC1 @ 19:35 - The Virus vs the Vaccine.

"With the country locked down again in the battle against coronavirus, Panorama reporter Clive Myrie asks what it will take to get through this latest, deadly stage of the pandemic. Hospitals are under pressure, with many said to be at breaking point. Once again, we’re being told to ‘stay at home, protect the NHS and save lives’. With schools shut and most exams cancelled, Panorama assesses the impact on young people’s mental health. The arrival of a vaccine offers hope, but its rollout is now in a race with a new, highly contagious strain of the virus."

[gazza] 11/1/2021 17:41

Bermuda, Have to agree, delivery method will be critical.

[bermudashorts] 11/1/2021 17:11

gooosed - thanks for your 35858 and think you're correct, Nottingham/Scancell are looking at inhaled version.

Inanaco - surprised you're not concerned about delivery. Delivery method is going to become an increasingly important factor in differentiating between second gen. vaccines. It's a crucially important part of SN14 and am looking forward to hearing more about the peptide delivery system being developed for Covidity.

[gazza] 11/1/2021 16:48

Inan,

"it works"

Do you not understand the difference between something that works and something that works AND comes out on top?

[inanaco] 11/1/2021 16:09

Oxford is already trying to compete with itself

VTP-950: A COVID-19 prophylactic
Unmet need
The COVID-19 pandemic continues to generate substantial pressure on health care systems and disrupt non-COVID-19 healthcare provision and the global economy. Further detriment to society is expected and the accelerated development of vaccines for prevention of COVID-19 is widespread.

Our approach
Preclinical data indicate Vaccitech’s new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease, when compared with the adenoviral platforms currently in vaccine trials for COVID-19. The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech’s research efforts.

Development Status
Vaccitech was awarded £155k for the first phase of the project worth up to £2.3m in funding. With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021. Depending on clinical success, the vaccine could be a standalone product candidate and/or could be used to improve upon regimens of first-generation COVID-19 vaccines. If successful, the same technology platform could also be used in future epidemics to produce a vaccine against the relevant infectious agent quickly and effectively.

[inanaco] 11/1/2021 16:02

Gazza

example

[inanaco] 11/1/2021 15:54

Gazza

"it works"

[inanaco] 11/1/2021 15:54

Moljen yes that is a very interesting product and they are running a trial that allows use by the NHS for emergency supply rather than a formal trial but that data adds to the approval process. I suspect it will be approved

[gazza] 11/1/2021 15:50

"Scancells still comes out Top "

Please explain which of the platforms has come out top and what criteria was used to make judgement.

[moljen] 11/1/2021 15:49

Inn - obviously not a vaccine but are you still following the SNG0001 treatment with it being an inhaler. Should be some news on trials coming out from them soon

[inanaco] 11/1/2021 15:42

Not really concerned about delivery ...

I do appreciate that a mass roll out does not lend to devices like Ichor

and a patch or inhaler does not necessarily induce a higher level of efficacy over a needle as you would need to test multiple delivery of the same vaccine and the developer would indeed pick the most efficacious

so its a platform v platform .......... not delivery v delivery

as GSK has found out some platforms are better than others

and History so far from cancer vaccines

Scancells still comes out Top ...

but the key now is sterilisation and variants

[inanaco] 11/1/2021 15:22

One thing we had not thought about is "current standard of care"




obviously for emergency use any vaccine developed should get approval if it induces over 70% efficacy but as the First three are rolled out ...

True Efficacy data will be produced .... giving future vaccines a min target to get approval ...



Sanofi and GSK now face a more difficult path because they may have to show their vaccine is at least as good as one already authorized by regulators. The Pfizer and Moderna vaccines have each shown that they are more than 90% effective against COVID-19.

Read more at:

[inanaco] 11/1/2021 14:21

LoL .. yes playing with Tosh does bring a dark side to the room

in fairness the universe we see is less than 10% of what we can't ... except when it appears ........Tosh with his legend £1000 trade

[emptyend] 11/1/2021 14:12

Its like I've gone through the wrong door and entered the secure wing by mistake........have some people not got lives?In other news, Kate Bingham is giving evidence to MPs at 2.30pm....live on SkyNews and doubtless elsewhere.